Compare VIRC & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | ONCY |
|---|---|---|
| Founded | 1950 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.5M | 94.0M |
| IPO Year | 1995 | 2002 |
| Metric | VIRC | ONCY |
|---|---|---|
| Price | $6.09 | $1.01 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.30 | ★ $7.33 |
| AVG Volume (30 Days) | 38.5K | ★ 966.8K |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $199,652,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.77 | $2,505.00 |
| P/E Ratio | $37.63 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.16 | $0.33 |
| 52 Week High | $9.63 | $1.51 |
| Indicator | VIRC | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 49.21 |
| Support Level | $6.02 | $0.94 |
| Resistance Level | $6.53 | $1.13 |
| Average True Range (ATR) | 0.27 | 0.09 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 71.96 | 46.97 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, and activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.